Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system
- PMID: 12857431
Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system
Abstract
In order to describe potential hypofibrinolytic tendencies in young (< 35 years) polycystic ovary syndrome (PCOS) patients, we studied plasminogen activator inhibitor (PAI-1) system components in women without laboratory evidence of hyperinsulinism or hyperandrogenism. The study was a prospective, observational comparison and took place in a major urban infertility referral center. Age, body mass index, ovulatory status, selected androgen levels, fasting insulin and plasma lipids were measured in subjects with PCOS (n = 39) and normal control subjects (n = 20). Women with PCOS had higher mean serum total testosterone and androstenedione levels compared with controls (56.4 versus 40.3 ng/dl, p = 0.03, and 179 versus 133 microg/ml, p = 0.03, respectively). Mean fasting insulin levels were higher among PCOS women (p < 0.01) and were strongly correlated with PAI-1 antigen (Ag) (r = 0.46), PAI-1 activity (r = 0.43), and tissue plasminogen activator (t-PA) (r = 0.5). Correlations were evident in both PCOS and control subjects. Mean PAI-1 Ag, PAI-1 activity, and t-PA levels were significantly elevated (p = 0.003, 0.001, and 0.001, respectively) in PCOS. ANOVA was performed to control for insulin effect; a trend toward elevated PAI-1 in PCOS persisted but was no longer statistically significant (p = 0.24). PAI-1 activity elevation remained in PCOS women with mean fasting insulin levels < 10 mIU/ml (p = 0.02), yet the difference became less significant when insulin was controlled (p = 0.38). Although these data confirm known associations between insulin and PAI-1 derangements, this is the first study to quantify discrete PAI-1 elevations that persist in the setting of PCOS even with normal or low ambient insulin levels. Additional prospective studies are needed to determine whether this altered PAI-1 state is associated with a clinically important hypofibrinolytic condition and subsequent poor reproductive outcome.
Similar articles
-
Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.Metabolism. 2006 Mar;55(3):345-52. doi: 10.1016/j.metabol.2005.09.008. Metabolism. 2006. PMID: 16483878
-
[Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].Zhonghua Fu Chan Ke Za Zhi. 2002 Feb;37(2):86-9. Zhonghua Fu Chan Ke Za Zhi. 2002. PMID: 11953071 Chinese.
-
Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.Gynecol Endocrinol. 2006 Nov;22(11):651-4. doi: 10.1080/09513590601005805. Gynecol Endocrinol. 2006. PMID: 17145652
-
Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1.Br J Dermatol. 1997 Mar;136(3):341-4. Br J Dermatol. 1997. PMID: 9115912 Review.
-
[Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. II. PAI-1 in insulin resistant conditions].Vnitr Lek. 1998 Feb;44(2):111-4. Vnitr Lek. 1998. PMID: 9820087 Review. Slovak.
Cited by
-
Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS.Endocrine. 2006 Aug;30(1):45-53. doi: 10.1385/ENDO:30:1:45. Endocrine. 2006. PMID: 17185791 Review.
-
Mediators of inflammation in polycystic ovary syndrome in relation to adiposity.Mediators Inflamm. 2010;2010:758656. doi: 10.1155/2010/758656. Epub 2010 Apr 8. Mediators Inflamm. 2010. PMID: 20396393 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous